Cardiac-specific deletion of SOCS-3 prevents development of left ventricular remodeling after acute myocardial infarction

Journal of the American College of Cardiology

Volumn 59, Issue 9, 2012, Pages 838-852

  Oba, Toyoharu ^a   Yasukawa, Hideo ^a,b   Hoshijima, Masahiko ^c   Sasaki, Ken Ichiro ^a,b   Futamata, Nobuyoshi ^a   Fukui, Daisuke ^a   Mawatari, Kazutoshi ^a   Nagata, Takanobu ^a   Kyogoku, Sachiko ^a   Ohshima, Hideki ^a   Minami, Tomoko ^a   Nakamura, Keiichiro ^a   Kang, Dongchon ^d   Yajima, Toshitaka ^c   Knowlton, Kirk U ^c   Imaizumi, Tsutomu ^a,b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

acute myocardial infarction; cytokine; JAK STAT; left ventricular remodeling; SOCS3

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; JANUS KINASE; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; REACTIVE OXYGEN METABOLITE; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE COURSE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE REMODELLING; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; GENE DELETION; HEART VENTRICLES; IN SITU NICK-END LABELING; MALE; MICE; MICE, INBRED BALB C; MYOCARDIAL INFARCTION; MYOCARDIUM; REAL-TIME POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84857341993     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.10.887     Document Type: Article

References (43)

1. G.W. Dorn 2nd Novel pharmacotherapies to abrogate postinfarction ventricular remodeling Nat Rev Cardiol 6 2009 283 291
2. D.L. Mann Mechanisms and models in heart failure: a combinatorial approach Circulation 100 1999 999 1008
3. M.G. Sutton, N. Sharpe Left ventricular remodeling after myocardial infarction: pathophysiology and therapy Circulation 101 2000 2981 2988
4. I. Kehat, J.D. Molkentin Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 122 2010 2727 2735
5. M. Harada, Y. Qin, H. Takano G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes Nat Med 11 2005 305 311
6. S. Minatoguchi, G. Takemura, X.H. Chen Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment Circulation 109 2004 2572 2580
7. K. Ueda, H. Takano, Y. Niitsuma Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice J Clin Invest 120 2010 2016 2029
8. H. Tada, Y. Kagaya, M. Takeda Endogenous erythropoietin system in non-hematopoietic lineage cells plays a protective role in myocardial ischemia/reperfusion Cardiovasc Res 71 2006 466 477
9. A. Hirata, T. Minamino, H. Asanuma Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs J Am Coll Cardiol 48 2006 176 184
10. M. Obana, M. Maeda, K. Takeda Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction Circulation 121 2010 684 691
11. C. Moon, M. Krawczyk, D. Ahn Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats Proc Natl Acad Sci U S A 100 2003 11612 11617
12. R. Bolli, B. Dawn, Y.T. Xuan Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury Trends Cardiovasc Med 13 2003 72 79
13. A. Haghikia, B. Stapel, M. Hoch, D. Hilfiker-Kleiner STAT3 and cardiac remodeling Heart Fail Rev 16 2011 35 47
14. K. Yamauchi-Takihara gp130-mediated pathway and heart failure Future Cardiol 4 2008 427 437
15. S.P. Barry, P.A. Townsend, D.S. Latchman, A. Stephanou Role of the JAK-STAT pathway in myocardial injury Trends Mol Med 13 2007 82 89
16. P. Fischer, D. Hilfiker-Kleiner Survival pathways in hypertrophy and heart failure: the gp130-STAT axis Basic Res Cardiol 102 2007 393 411
17. H. Yasukawa, A. Sasaki, A. Yoshimura Negative regulation of cytokine signaling pathways Annu Rev Immunol 18 2000 143 164
18. H. Yasukawa, H. Misawa, H. Sakamoto The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop EMBO J 18 1999 1309 1320
19. A. Sasaki, H. Yasukawa, T. Shouda, T. Kitamura, I. Dikic, A. Yoshimura CIS3/SOCS-3 suppresses erythropoietin (EPO) signaling by binding the EPO receptor and JAK2 J Biol Chem 275 2000 29338 29347
20. H. Yasukawa, M. Hoshijima, Y. Gu Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways J Clin Invest 108 2001 1459 1467
21. H. Yasukawa, T. Yajima, H. Duplain The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury J Clin Invest 111 2003 469 478
22. T. Yajima, H. Yasukawa, E.S. Jeon Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling Circulation 114 2006 2364 2373
23. H. Yasukawa, M. Ohishi, H. Mori IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages Nat Immunol 4 2003 551 556
24. H. Mori, R. Hanada, T. Hanada Socs3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity Nat Med 10 2004 739 743
25. R. Agah, P.A. Frenkel, B.A. French, L.H. Michael, P.A. Overbeek, M.D. Schneider J Clin Invest 100 1997 169 179
26. M. Ikeuchi, H. Matsusaka, D. Kang Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction Circulation 112 2005 683 690
27. M. Sano, M.D. Schneider Energizer: PGC-1 alpha keeps the heart going Cell Metab 1 2005 216 218
28. H. Tsutsui, S. Kinugawa, S. Matsushima Mitochondrial oxidative stress and dysfunction in myocardial remodelling Cardiovasc Res 81 2009 449 456
29. T. Ago, J. Sadoshima Thioredoxin and ventricular remodeling J Mol Cell Cardiol 41 2006 762 773
30. S. Negoro, K. Kunisada, Y. Fujio Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation- induced oxidative stress through the upregulation of manganese superoxide dismutase Circulation 104 2001 979 981
31. B. Dawn, R. Bolli HO-1 induction by HIF-1: a new mechanism for delayed cardioprotection? Am J Physiol Heart Circ Physiol 289 2005 H522 H524
32. Y. Fujio, K. Kunisada, H. Hirota, K. Yamauchi-Takihara, T. Kishimoto Signals through gp130 upregulate bcl-x gene expression via STAT1-binding cis-element in cardiac myocytes J Clin Invest 99 1997 2898 2905
33. D.J. Hausenloy, D.M. Yellon Cardioprotective growth factors Cardiovasc Res 83 2009 179 194
34. J. Wegrzyn, R. Potla, Y.J. Chwae Function of mitochondrial Stat3 in cellular respiration Science 323 2009 793 797
35. D. Kang, S.H. Kim, N. Hamasaki Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions Mitochondrion 7 2007 39 44
36. J.E. Jung, G.S. Kim, P. Narasimhan, Y.S. Song, P.H. Chan Regulation of Mn-superoxide dismutase activity and neuroprotection by STAT3 in mice after cerebral ischemia J Neurosci 29 2009 7003 7014
37. X. Zhang, P. Shan, G. Jiang Endothelial STAT3 is essential for the protective effects of HO-1 in oxidant-induced lung injury FASEB J 20 2006 2156 2158
38. H. Okada, G. Takemura, Y. Li Effect of a long-term treatment with a low-dose granulocyte colony-stimulating factor on post-infarction process in the heart J Cell Mol Med 12 2008 1272 1283
39. H. Kobayashi, S. Minatoguchi, S. Yasuda Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair Cardiovasc Res 79 2008 611 620
40. J.J. Jacoby, A. Kalinowski, M.G. Liu Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age Proc Natl Acad Sci U S A 100 2003 12929 12934
41. S.S. Najjar, S.V. Rao, C. Melloni Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial JAMA 305 2011 1863 1872
42. H. Sakamoto, H. Yasukawa, M. Masuhara A Janus kinase inhibitor, JAB, is an interferon-gamma-inducible gene and confers resistance to interferons Blood 92 1998 1668 1676
43. I. Hamanaka, Y. Saito, H. Yasukawa Induction of JAB/SOCS-1/SSI-1 and CIS3/SOCS-3/SSI-3 is involved in gp130 resistance in cardiovascular system in rat treated with cardiotrophin-1 in vivo Circ Res 88 2001 727 732